Hasta Phrmaceutical Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.97 Cr
- Company Age 28 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.25 M
- Revenue Growth %
- Profit Growth -2230.07%
- Ebitda -6690.22%
- Net Worth -2.87%
- Total Assets -12.24%
About Hasta Phrmaceutical
Hasta Phrmaceutical Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 March 1996 and has a history of 28 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.97 Cr.
The company currently has active open charges totaling ₹0.25 M.
Ankit Jain and Prajesh Mehta serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24110MH1996PTC098258
- Company No.
098258
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Mar 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Hasta Phrmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankit Jain  | Director | 30-Sep-2003 | Current |
| Prajesh Mehta | Director | 19-Mar-2019 | Current |
Financial Performance of Hasta Phrmaceutical.
Hasta Phrmaceutical Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 2230.07% decrease in profit. The company's net worth dipped by a decrease of 2.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hasta Phrmaceutical?
In 2019, Hasta Phrmaceutical had a promoter holding of 22.41% and a public holding of 77.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vnurture Healthcare Software Solutions Private LimitedAnkit Jain is a mutual person
Jvpd One Private LimitedAnkit Jain is a mutual person
Charges (Loans)
₹0.03 Cr
₹0
Charges Breakdown by Lending Institutions
- The Saraswat Co Op. Bank : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Apr 2000 | The Saraswat Co Op. Bank | ₹0.25 M | Open |
How Many Employees Work at Hasta Phrmaceutical?
Unlock and access historical data on people associated with Hasta Phrmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hasta Phrmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hasta Phrmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
